Michael Wenger to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Michael Wenger has written about Drug Resistance, Neoplasm.
Connection Strength
0.035
-
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019 May; 6(5):e254-e265.
Score: 0.035